Publications by authors named "Runyu Dong"
Introduction: Cisplatin-based chemotherapy is one of the fundamental therapeutic modalities for gastric cancer (GC). Chemoresistance to cisplatin is a great clinical challenge, and its underlying mechanisms remain poorly understood. Circular RNAs (circRNAs) are involved in the pathophysiology of multiple human malignancies.
View Article and Find Full Text PDFBackground: Circular RNAs (circRNAs) have been implicated in the development and progression of gastric cancer (GC). However, it remains unclear whether dysregulated circRNA affects immune escape and the efficacy of immunotherapy in GC. Our aim is to investigate the molecular mechanism of circRNA affecting GC immunotherapy and identify effective molecular therapeutic targets.
View Article and Find Full Text PDFBackground: Cuproptosis, as a unique modality of regulated cell death, requires the involvement of ubiquitin-binding enzyme UBE2D2. However, the prognostic and immunotherapeutic values of UBE2D2 in pan-cancer remain largely unknown.
Methods: Using UCSC Xena, TIMER, Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Human Protein Atlas (HPA) databases, we aimed to explore the differential expression pattern of UBE2D2 across multiple cancer types and to evaluate its association with patient prognosis, clinical features, and genetic variations.
Primary liver cancer is the sixth most common cancer and the third leading cause of cancer-related death worldwide. The role of the 'Other' subfamily of HECT E3 ligases (E3s) in hepatocellular carcinoma (HCC) remains unknown. The expression of the 'Other' HECT E3s was performed using The Cancer Genome Atlas (TCGA) data, and the authors found that the 'Other' HECT E3s were differentially expressed in HCC.
View Article and Find Full Text PDFArticle Synopsis
- Hypoxia in tumors contributes to their progression and resistance to immune responses, making it a target for innovative cancer therapies like TH-302, which is designed to be activated in low-oxygen conditions.
- Researchers created TH-302 nanoparticles (TH-302 NPs) to specifically attack hypoxic tumor areas and conducted various tests to analyze their size, safety, and effects on gastric cancer cells, both in lab settings and in live subjects.
- Results showed that TH-302 NPs not only inhibited cancer cell growth and promoted cell death in low-oxygen environments but also improved immune responses when used with anti-PD-1 therapy, ultimately enhancing overall treatment effectiveness.